Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14153027 | 1.00 | EPHX1 (0.35) | EPHX1CYP1A2ALDH1A1S1PR2S1PR4 | |
| SCHEMBL11705481 | 1.00 | EPHX1 (0.35) | EPHX1CYP1A2ALDH1A1S1PR2S1PR4 | |
| SCHEMBL10620419 | 0.98 | EPHX1 (0.38) | EPHX1CYP1A2ALDH1A1S1PR2S1PR4 | |
| SCHEMBL12161640 | 0.98 | EPHX1 (0.38) | EPHX1CYP1A2ALDH1A1S1PR2S1PR4 | |
| SCHEMBL7711924 | 0.98 | EPHX1 (0.38) | EPHX1CYP1A2ALDH1A1S1PR2S1PR4 | |
| SCHEMBL10773640 | 0.98 | EPHX1 (0.38) | EPHX1CYP1A2ALDH1A1S1PR2S1PR4 | |
| SCHEMBL14976126 | 0.98 | EPHX1 (0.38) | EPHX1CYP1A2ALDH1A1S1PR2S1PR4 | |
| SCHEMBL18937149 | 0.94 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL18937148 | 0.94 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL1419553 | 0.94 | CYP1A2 (0.40) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | EPHX1 587/4885CYP1A2 10/4885ALDH1A1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.